TW202227421A - Ｇｌｐ－１ｒ促效劑的晶型及其用途 - Google Patents

Ｇｌｐ－１ｒ促效劑的晶型及其用途 Download PDF

Info

Publication number
TW202227421A
TW202227421A TW110138006A TW110138006A TW202227421A TW 202227421 A TW202227421 A TW 202227421A TW 110138006 A TW110138006 A TW 110138006A TW 110138006 A TW110138006 A TW 110138006A TW 202227421 A TW202227421 A TW 202227421A
Authority
TW
Taiwan
Prior art keywords
disease
compound
crystal form
ray powder
powder diffraction
Prior art date
Application number
TW110138006A
Other languages
English (en)
Chinese (zh)
Inventor
鐘文革
郭巍
征 李
姜夏偉
陳鵬源
Original Assignee
大陸商上海齊魯銳格醫藥研發有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海齊魯銳格醫藥研發有限公司 filed Critical 大陸商上海齊魯銳格醫藥研發有限公司
Publication of TW202227421A publication Critical patent/TW202227421A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW110138006A 2020-10-14 2021-10-13 Ｇｌｐ－１ｒ促效劑的晶型及其用途 TW202227421A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020120814 2020-10-14
WOPCT/CN2020/120814 2020-10-14

Publications (1)

Publication Number Publication Date
TW202227421A true TW202227421A (zh) 2022-07-16

Family

ID=78401981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110138006A TW202227421A (zh) 2020-10-14 2021-10-13 Ｇｌｐ－１ｒ促效劑的晶型及其用途

Country Status (9)

Country Link
US (1) US20230382899A1 (enExample)
EP (1) EP4228753B1 (enExample)
JP (1) JP7769695B2 (enExample)
CN (1) CN116710446B (enExample)
AU (1) AU2021359493A1 (enExample)
CA (1) CA3195264A1 (enExample)
ES (1) ES3041328T3 (enExample)
TW (1) TW202227421A (enExample)
WO (1) WO2022078352A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024017266A1 (zh) * 2022-07-18 2024-01-25 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂的多晶型物及其制备方法与用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114761395B (zh) * 2019-12-02 2024-11-15 现代药品株式会社 Glp-1受体激动剂
WO2023049518A1 (en) 2021-09-27 2023-03-30 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20250741A1 (es) 2022-02-23 2025-03-13 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
CN117362282A (zh) * 2022-07-07 2024-01-09 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
EP4568664A1 (en) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2262364B1 (en) 2008-03-07 2016-03-02 vTv Therapeutics LLC Oxadiazoanthracene compounds for the treatment of diabetes
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MA56480B1 (fr) 2016-12-16 2022-12-30 Pfizer Agonistes du récepteur glp-1 et leurs utilisations
EP3806855B1 (en) 2018-06-15 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CU20210042A7 (es) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
CR20210562A (es) * 2019-04-12 2022-02-18 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024017266A1 (zh) * 2022-07-18 2024-01-25 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂的多晶型物及其制备方法与用途

Also Published As

Publication number Publication date
JP7769695B2 (ja) 2025-11-13
US20230382899A1 (en) 2023-11-30
JP2023546125A (ja) 2023-11-01
EP4228753B1 (en) 2025-07-30
AU2021359493A9 (en) 2025-01-09
WO2022078352A1 (en) 2022-04-21
ES3041328T3 (en) 2025-11-11
EP4228753A1 (en) 2023-08-23
CN116710446A (zh) 2023-09-05
CA3195264A1 (en) 2022-04-21
CN116710446B (zh) 2024-10-18
AU2021359493A1 (en) 2023-06-15
EP4228753C0 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
JP7702973B2 (ja) Ｇｌｐ－１ｒアゴニストの塩及び結晶形態、並びにそれらの使用
TW202227421A (zh) Ｇｌｐ－１ｒ促效劑的晶型及其用途
TWI809334B (zh) ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
TWI839416B (zh) Ｇｌｐ-１ｒ促效劑及其用途
TWI840348B (zh) G蛋白偶聯受體調節劑
TW202214622A (zh) Ｇｌｐ－１ｒ促效劑及其用途
CN115667250A (zh) 杂环glp-1激动剂
US20230201185A1 (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2023066356A1 (zh) 作为glp-1受体激动剂的化合物及其用途
US20250214968A1 (en) Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
CN120712261A (zh) 杂环的glp-1激动剂
CN120693338A (zh) 杂环的glp-1激动剂
CN103420981A (zh) 含有取代吡咯烷基的硫代吗啉类化合物
HK40089377A (en) Crystal forms of glp-1r agonists and uses thereof
HK40089377B (en) Crystal forms of glp-1r agonists and uses thereof
CN104211702B (zh) 取代黄嘌呤类化合物及其制备方法和用途
HK40087545B (en) Salt and crystal forms of glp-1r agonists and uses thereof
HK40087545A (en) Salt and crystal forms of glp-1r agonists and uses thereof
CN110256461A (zh) 稠杂嘧啶衍生物及其制备方法和应用
CN109942583B (zh) 芳基取代的氨基四氢吡喃类化合物及其用途
TW202539633A (zh) 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2023111817A1 (en) Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
HK40085148B (zh) 杂环glp-1激动剂